Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Disease symbols : Ganx save search
Gain Therapeutics Presents Data at the AD/PD™ 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson’s Disease
Published: 2024-03-05 (Crawled : 13:00) - globenewswire.com
GANX | $3.155 0.16% 0.16% 71K
|
Professional, Scientific, and T...
|
| O: -4.66%
H: 6.67%
C: 3.56%
gt-0228 conference disease treatment parkinson’s therapeutics
Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
Published: 2024-02-27 (Crawled : 19:00) - globenewswire.com
GANX | $3.155 0.16% 0.16% 71K
|
Professional, Scientific, and T...
|
| O: 0.22%
H: 3.45%
C: -3.88%
gt-0228 disease parkinson’s trial therapeutics therapy
Gain Therapeutics Announces 2024 R&D Update on Parkinson’s Disease with KOL & Analyst Insight
Published: 2024-02-14 (Crawled : 18:00) - globenewswire.com
GANX | $3.155 0.16% 0.16% 71K
|
Professional, Scientific, and T...
|
| O: 0.0%
H: 5.32%
C: 4.88%
disease update parkinson’s therapeutics
UPDATE - Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease
Published: 2024-02-06 (Crawled : 15:00) - globenewswire.com
GANX | $3.155 0.16% 0.16% 71K
|
Professional, Scientific, and T...
|
| O: -0.46%
H: 7.55%
C: 2.29%
gt-0228 disease update parkinson’s
Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease
Published: 2024-02-06 (Crawled : 13:00) - globenewswire.com
GANX | $3.155 0.16% 0.16% 71K
|
Professional, Scientific, and T...
|
| O: -0.46%
H: 7.55%
C: 2.29%
gt-0228 disease parkinson’s
Gain Therapeutics Announces Dosing of First Two Subjects in Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
Published: 2023-10-04 (Crawled : 11:00) - globenewswire.com
GANX | $3.155 0.16% 0.16% 71K
|
Professional, Scientific, and T...
|
| O: -2.06%
H: 2.8%
C: -4.65%
gt-0228 disease parkinson’s trial therapeutics therapy
Gain Therapeutics Presents New Preclinical Data Demonstrating a Reduction of Plasma Neurodegeneration Biomarker NfL after Administration of its Drug Candidate GT-02287 in GBA1 Parkinson’s Disease Model
Published: 2023-08-28 (Crawled : 11:00) - globenewswire.com
GANX | $3.155 0.16% 0.16% 71K
|
Professional, Scientific, and T...
|
| O: -0.28%
H: 6.55%
C: -1.71%
gt-0228 drug candidate disease biomarker preclinical parkinson’s therapeutics
Gain Therapeutics Announces Acceptance of Late Breaking Abstract for Presentation at the International Congress of Parkinson’s Disease and Movement Disorders®
Published: 2023-08-07 (Crawled : 11:00) - globenewswire.com
GANX | $3.155 0.16% 0.16% 71K
|
Professional, Scientific, and T...
|
| O: -0.26%
H: 0.79%
C: -0.26%
disorders disease presentation international parkinson’s therapeutics
Gain Therapeutics Awarded CHF 2.5 million Innosuisse Grant to Advance Lead Program in GBA1 Parkinson’s Disease
Published: 2023-05-03 (Crawled : 13:20) - globenewswire.com
GANX | $3.155 0.16% 0.16% 71K
|
Professional, Scientific, and T...
|
| O: 0.29%
H: 0.57%
C: -1.71%
disease grant program parkinson’s therapeutics
Gain Therapeutics Presents New Preclinical Data Showing Promising Pharmacological Activity in Parkinson’s Disease Patient-Derived Dopaminergic Neurons
Published: 2022-09-26 (Crawled : 14:00) - biospace.com/
GANX | $3.155 0.16% 0.16% 71K
|
Professional, Scientific, and T...
|
| O: -2.4%
H: 6.96%
C: 0.92%
disease preclinical parkinson’s therapeutics
Gain Therapeutics Presents New Preclinical Data Demonstrating Potential Disease Modifying Benefits of its Novel Brain Penetrant Small Molecule Candidate GT-02287 in Two Preclinical Models of Parkinson’s Disease
Published: 2022-09-19 (Crawled : 17:00) - biospace.com/
GANX | $3.155 0.16% 0.16% 71K
|
Professional, Scientific, and T...
|
| O: -3.17%
H: 1.37%
C: -4.35%
gt-0228 candidate disease preclinical parkinson’s therapeutics potential benefits train
Gain Therapeutics Presents Positive Preclinical Data On Its Gaucher Disease Program at IWGGD Symposium
Published: 2022-05-11 (Crawled : 14:00) - globenewswire.com
GANX | $3.155 0.16% 0.16% 71K
|
Professional, Scientific, and T...
|
| O: 0.31%
H: 9.38%
C: -13.44%
disease preclinical symposium program therapeutics positive pre-clinical
Gain Therapeutics Presents Positive Data on its Small Molecule Lead Compound in GBA1 Parkinson’s Disease at the 2022 Synuclein Meeting
Published: 2022-04-12 (Crawled : 18:00) - globenewswire.com
GANX | $3.155 0.16% 0.16% 71K
|
Professional, Scientific, and T...
|
| O: 5.97%
H: 50.9%
C: -12.61%
therapeutics positive disease
Gain Therapeutics Presents Positive Data on its Structurally Targeted Allosteric Regulators in both Parkinson’s and Alzheimer’s Disease at the AD/PD 2022 Conference
Published: 2022-03-15 (Crawled : 13:30) - biospace.com/
GANX | $3.155 0.16% 0.16% 71K
|
Professional, Scientific, and T...
|
| O: 9.7%
H: 2.76%
C: -7.46%
alzheimer pos parkinson conference therapeutics disease positive alzheimer’s alzheimer's disease alzheimer's
Gain Therapeutics Presents Preclinical Data on its Structurally Targeted Allosteric Regulators in GBA1 Gaucher Disease
Published: 2022-02-08 (Crawled : 19:00) - biospace.com/
GANX | $3.155 0.16% 0.16% 71K
|
Professional, Scientific, and T...
|
| O: -0.54%
H: 2.09%
C: -6.3%
therapeutics disease preclinical pre-clinical
Gain Therapeutics Progresses Krabbe Disease Program and Provides Scientific UpdateData Show Statistically Significant Increases in GALC Enzyme and Depletion of Toxic Substrate Psychosine
Published: 2021-12-07 (Crawled : 15:00) - biospace.com/
GANX | $3.155 0.16% 0.16% 71K
|
Professional, Scientific, and T...
|
| O: 1.52%
H: 8.67%
C: 7.17%
therapeutics disease
Gain Therapeutics Presents Parkinson’s Disease Preclinical Study Results at Society for Neuroscience Annual Meeting
Published: 2021-11-11 (Crawled : 17:00) - globenewswire.com
GANX | $3.155 0.16% 0.16% 71K
|
Professional, Scientific, and T...
|
| O: 0.51%
H: 0.0%
C: -5.2%
disease results parkinson preclinical pre-clinical
Gain Therapeutics, Inc. Announces Breakthrough Pre-Clinical Data of Novel Small Molecules for the Treatment of Parkinson’s Disease and Gaucher Disease
Published: 2021-11-10 (Crawled : 17:00) - biospace.com/
GANX | $3.155 0.16% 0.16% 71K
|
Professional, Scientific, and T...
|
| O: 0.98%
H: 18.65%
C: 8.43%
disease treatment pre-clinical parkinson preclinical
Gain Therapeutics, Inc. Announces Positive Topline Data in Patient-derived iPSC Study Evaluating STAR Compounds as a Treatment for Gaucher and Parkinson’s Disease
Published: 2021-09-08 (Crawled : 13:15) - globenewswire.com
GANX | $3.155 0.16% 0.16% 71K
|
Professional, Scientific, and T...
|
| O: 19.11%
H: 3.61%
C: 0.85%
disease treatment positive topline parkinson
Gain Therapeutics Presents Positive In Vitro & In Vivo Data on Its Orally Bioavailable Brain Penetrant Star Compounds for the Treatment of GBA1 Parkinson’s Disease & Related α-synucleopathies at the XXVI IAPRD World Congress
Published: 2021-05-03 (Crawled : 12:00) - biospace.com/
GANX | $3.155 0.16% 0.16% 71K
|
Professional, Scientific, and T...
|
| O: 0.08%
H: 0.2%
C: -4.71%
disease treatment positive leo parkinson train in vitro
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.